The National Health Insurance Administration and the National Health Commission issued “Certain Measures to Support the High-Quality Development of Innovative Drugs”, which proposed supporting the use of health insurance data for innovative drug research and development. Strengthen information exchange and collaboration between medical care, medical insurance, and medicine, do a good job in the management of health insurance data resources, and promote the use of public data resources in the health insurance field. On the basis of ensuring data security and legal compliance, explore the provision of necessary medical insurance data services for innovative drug research and development. Relying on a unified national medical insurance information platform, we collect and analyze data such as disease spectrum and clinical medication requirements, develop data products adapted to the R&D needs of innovative drugs, and support pharmaceutical companies, research institutes, medical institutions, etc. to rationally determine R&D direction and lay out R&D pipelines to improve innovation efficiency.

Zhitongcaijing · 07/01 01:41
The National Health Insurance Administration and the National Health Commission issued “Certain Measures to Support the High-Quality Development of Innovative Drugs”, which proposed supporting the use of health insurance data for innovative drug research and development. Strengthen information exchange and collaboration between medical care, medical insurance, and medicine, do a good job in the management of health insurance data resources, and promote the use of public data resources in the health insurance field. On the basis of ensuring data security and legal compliance, explore the provision of necessary medical insurance data services for innovative drug research and development. Relying on a unified national medical insurance information platform, we collect and analyze data such as disease spectrum and clinical medication requirements, develop data products adapted to the R&D needs of innovative drugs, and support pharmaceutical companies, research institutes, medical institutions, etc. to rationally determine R&D direction and lay out R&D pipelines to improve innovation efficiency.